FrancophonIA/ELRC3.0 huggingface dataset:
English: Warfarin The effects of Enviage on warfarin pharmacokinetics have not been evaluated.
Estonian: Varfariin Enviage mõju varfariini farmakokineetikale ei ole kindlaks määratud.
English: Co-administration of aliskiren with either valsartan (↓28%), metformin (↓28%), amlodipine (↑29%) or cimetidine (↑19%) resulted in between 20% and 30% change in Cmax or AUC of Enviage.
Estonian: Aliskireeni manustamisel koos valsartaani (↓28%), metformiini (↓28%), amlodipiini (↑29%) või tsimetidiiniga (↑19%) muutus Enviage Cmax või AUC 20...30%.
English: In the event of severe and persistent diarrhoea, Enviage therapy should be stopped.
Estonian: Tugeva ja püsiva kõhulahtisuse tekkimisel tuleb ravi Enviage'ga katkestada.
English: Enviage did not affect the serum concentration of creatinine but was associated with an increased frequency (4.2% vs. 1.9% for placebo) of serum potassium concentration ≥6.0 mmol/l, although this was not statistically significant.
Estonian: Enviage ei mõjutanud kreatiniini seerumi kontsentratsiooni, aga oli seotud kaaliumi seerumi kontsentratsiooni ≥ 6,0 mmol/1 suurenenud sagedusega (4,2% võrredles 1,9% platseebol), kuigi see ei olnud statistiliselt tähelepanuväärne.
English: In patients with marked volume- and/or salt-depletion (e.g. those receiving high doses of diuretics) symptomatic hypotension could occur after initiation of treatment with Enviage.
Estonian: Väljendunud naatriumi- ja/või vedelikuvaegusega (nt diureetikumi suuri annuseid saavatel) patsientidel võib Enviage-ravi alustamise järgselt tekkida sümptomaatiline hüpotensioon.
English: As a result no dose adjustment for Enviage or these co-administered medicinal products is necessary.
Estonian: Selle tulemusena ei ole vaja muuta Enviage või teiste samaaegselt manustatavate ravimite annust.
English: INFORMATION IN BRAILLE Enviage 300 mg
Estonian: INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Enviage 300 mg
English: Caution should be exercised in hypertensive patients with severe renal impairment due to the lack of safety information for Enviage.
Estonian: Raske neerukahjustusega hüpertensiivsete patsientide ravimisel tuleb olla ettevaatlik, kuna Enviage kohta ohutusandmed puuduvad.
English: In controlled clinical trials, angioedema occurred rarely during treatment with Enviage with rates comparable to treatment with placebo or hydrochlorothiazide.
Estonian: Kontrollitud kliinilistes uuringutes tekkis angioödeem ravi ajal Enviage'ga harva ning esinemissagedus oli võrreldav platseebo või hüdroklorotiasiidiga.
English: In clinical studies in hypertensive patients, Enviage had no clinically important effects on total cholesterol, high density lipoprotein cholesterol (HDL-C), fasting triglycerides, fasting glucose or uric acid.
Estonian: Hüpertensiivsete patsientidega läbiviidud kliinilistes uuringutes ei olnud Enviage'l kliiniliselt olulist mõju üldkolesterooli, kõrge tihedusega lipoproteiin (HDL) kolesterooli, tühja kõhuga triglütseriidide, tühja kõhuga glükoosi- või kusihappe sisaldusele.
English: In patients who did not adequately respond to 5 mg of the calcium channel blocker amlodipine, the addition of Enviage 150 mg had a blood-pressure-lowering effect similar to that obtained by increasing amlodipine dose to 10 mg, but had a lower incidence of oedema (aliskiren 150 mg/amlodipine 5 mg 2.1% vs. amlodipine 10 mg 11.2%).
Estonian: Patsientidel, kellel ei olnud saavutatud piisavat ravivastust 5 mg kaltsiumikanali blokaatori amlodipiini kasutamisel, tagas 150 mg Enviage lisamine vererõhku langetava toime, mis saavutati sarnaselt amlodipiini annuse suurendamisega 10 mg-ni, kuid tursete esinemissagedus oli väiksem (aliskireen 150 mg/amlodipiin 5 mg 2,1% vs. amlodipiin 10 mg 11,2%).
English: Compared to a diuretic (hydrochlorothiazideHCTZ), Enviage 300 mg lowered systolic/diastolic blood pressure by 17.0/12.3 mmHg, compared to 14.4/10.5 mmHg for HCTZ 25 mg after 12 weeks of treatment.
Estonian: Diureetikumiga (hüdroklorotiasiidHCTZ) võrreldes langetas Enviage 300 mg süstoolset/diastoolset vererõhku 17,0/12,3 mmHg võrra, võrreldes langusega 14,4/10,5 mmHg võrra HCTZ 25 mg toimel 12 ravinädala möödudes.
English: In a 6-month study of 599 patients with hypertension, type 2 diabetes mellitus, and nephropathy, all of whom were receiving losartan 100 mg and optimised antihypertensive background therapy, addition of Enviage 300 mg achieved a 20% reduction versus placebo in urinary albumin:creatinine ratio (UACR), i.e. from 58 mg/mmol to 46 mg/mmol.
Estonian: 6-kuulises uuringus, kus osales 599 hüpertensiooniga, II tüüpi diabeediga ja nefropaatiaga patsienti, kes said 100 mg losartaani ja optimeeritud antihüpertensiivset foonravi, viis Enviage 300 mg'i lisamine 20%-lise albumiin:kreatiniini suhte languseni uriinis (UACR), võrreldes platseeboga, 58 mg/mmol-lt 46 mg/mmol-le.
English: Serum potassium: Increases in serum potassium were minor and infrequent in patients with essential hypertension treated with Enviage alone (0.9% compared to 0.6% with placebo).
Estonian: Seerumi kaaliumisisaldus: Seerumi kaaliumisisalduse suurenemine oli vähene ja tekkis harva arteriaalse hüpertensiooniga patsientidel, kes said raviks ainult Enviage't (0,9% võrreldes 0,6%-ga platseebo puhul).
English: Take special care with Enviage - if you are taking a diuretic (a type of medicine also known as “water” tablets which increases the amount of urine you produce).
Estonian: Eriline ettevaatus on vajalik ravimiga Enviage - kui te võtate diureetikumi (teatud tüüpi ravim, mida nimetatakse ka „vett väljaviivateks”
English: No controlled clinical data are available on the use of Enviage in patients with unilateral or bilateral renal artery stenosis, or stenosis to a solitary kidney.
Estonian: Puuduvad kontrollitud kliinilised andmed Enviage kasutamise kohta ühe- või kahepoolse neeruarteri stenoosiga või ainsat neeru varustava neeruarteri stenoosiga patsientidel.
English: Digoxin bioavailability may be slightly decreased by Enviage.
Estonian: Enviage võib veidi vähendada digoksiini biosaadavust.
English: INFORMATION IN BRAILLE Enviage 150 mg
Estonian: INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Enviage 150 mg
English: Do not breast-feed if you are taking Enviage.
Estonian: Ärge toitke last rinnaga, kui te võtate Enviage't.
English: Inducers of P-gp (St. John's wort, rifampicin) might therefore decrease the bioavailability of Enviage.
Estonian: P-gp indutseerijad (naistepuna, rifampitsiin) võivad seetõttu vähendada Enviage biosaadavust.
English: Excessive hypotension was uncommonly (0.1%) seen in patients with uncomplicated hypertension treated with Enviage alone.
Estonian: Ülemäärast vererõhu langust täheldati aeg-ajalt (0,1%) tüsistumata hüpertensiooniga patsientidel, kes said Enviage't monoteraapiana.
English: Enviage may be used alone or in combination with other antihypertensive agents (see sections 4.4 and
Estonian: Enviage't võib kasutada monoteraapiana või kombinatsioonis teiste antihüpertensiivsete ravimitega (vt lõigud 4.4 ja 5.1).
English: In obese hypertensive patients who did not adequately respond to HCTZ 25 mg, add-on treatment with Enviage 300 mg provided additional blood pressure reduction that was comparable to add-on treatment with irbesartan 300 mg or amlodipine 10 mg.
Estonian: Ülekaalulistel hüpertensiivsetel patsientidel, kellel ei saavutatud piisavat ravivastust HCTZ 25 mg kasutamisel, tagas 300 mg Enviage lisamine täiendava vererõhu languse, mis oli võrreldav 300 mg irbesartaani või 10 mg amlodipiini lisamisel saavutatud toimega.
English: Combination therapy studies are available for Enviage added to the diuretic hydrochlorothiazide, the ACEI ramipril, the calcium channel blocker amlodipine, the angiotensin receptor antagonist valsartan, and the beta blocker atenolol.
Estonian: Kombinatsioonravi uuringud on olemas Enviage lisamisel hüdroklorotiasiidile (diureetikum), ramipriilile (AKE inhibiitor), amlodipiinile (kaltsiumikanali blokaator), valsartaanile (angiotensiini retseptori antagonist) ja atenoloolile (beetablokaator).
English: Coadministration of Enviage had no significant impact on atorvastatin, valsartan, metformin or amlodipine pharmacokinetics.
Estonian: Enviage samaaegsel manustamisel puudus oluline mõju atorvastatiini, valsartaani, metformiini või amlodipiini farmakokineetikale.
English: Enviage is available in packs containing 7, 14, 28, 30, 50, 56, 84, 90, 98 or 280 tablets.
Estonian: Enviage tablette on 7, 14, 28, 30, 50, 56, 84, 90, 98 või 280 tk pakendis.
English: In controlled clinical trials, clinically relevant changes in standard laboratory parameters were uncommonly associated with the administration of Enviage.
Estonian: Kontrollitud kliinilistes uuringutes tekkis Enviage manustamisel harva standardsete laboratoorsete näitajate kliiniliselt olulisi muutusi.
English: In hypertensive patients, once-daily administration of Enviage at doses of 150 mg and 300 mg provided dose-dependent reductions in both systolic and diastolic blood pressure that were maintained over the entire 24-hour dose interval (maintaining benefit in the early morning) with a mean peak to trough ratio for diastolic response of up to 98% for the 300 mg dose.
Estonian: Hüpertensiivsetel patsientidel viis Enviage 150 mg ja 300 mg annuste üks kord päevas manustamine nii süstoolse kui diastoolse vererõhu annusest sõltuva languseni, mis püsis kogu 24-tunnise manustamisintervalli jooksul (toime püsimine varastel hommikutundidel) ning 300 mg annuse puhul oli keskmine maksimaalse ja minimaalse kontsentratsiooni suhe kuni 98%.
English: No adjustment of the initial dosage of Enviage is required in patients with mild to severe renal impairment, however caution should be exercised in patients with severe renal impairment.
Estonian: Kerge kuni raske neerukahjustusega patsientidel ei ole vaja Enviage algannust muuta, ent raske neerukahjustusega patsientide ravimisel tuleb olla ettevaatlik.
English: Enviage monotherapy studies have shown blood pressure lowering effects comparable to other classes of antihypertensive agents including ACEI and ARB.
Estonian: Enviage monoteraapia uuringutes on täheldatud teiste antihüpertensiivsete ravimite rühmadega (AKE inhibiitorid ja ARB) võrreldavat vererõhku langetavat toimet.
English: Treatment with Enviage resulted in an overall incidence of adverse reactions similar to placebo up to 300 mg.
Estonian: Enviage-ravi puhul oli kuni 300 mg annuseni kõrvaltoimete üldine esinemissagedus sarnane platseeboga.
English: When administered with atorvastatin, steady-state Enviage AUC and Cmax increased by 50%.
Estonian: Koos atorvastatiiniga manustamisel suurenesid Enviage püsikontsentratsiooni faasi AUC ja Cmax 50%.
English: Enviage has negligible influence on the ability to drive and use machines.
Estonian: Enviage ei oma märkimisväärset toimet autojuhtimise ja masinate käsitsemise võimele.
English: Enviage was secreted in the milk of lactating rats.
Estonian: Enviage eritus lakteerivate rottide piima.
English: There are no data on the use of aliskiren in pregnant women.
Estonian: Enviage kasutamise kohta rasedatel ei ole piisavalt andmeid.
English: Angioedema has occurred during treatment with Enviage.
Estonian: Ravi ajal Enviage'ga on esinenud angioödeemi.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/07/406/007
Estonian: MÜÜGILOA NUMBER (NUMBRID) EU/1/07/406/001
English: Enviage 300 mg film-coated tablets Aliskiren
Estonian: Enviage 300 mg õhukese polümeerikattega tabletid Aliskireen
English: Enviage 150 mg film-coated tablets Aliskiren
Estonian: Enviage 150 mg õhukese polümeerikattega tabletid Aliskireen
English: Enviage in combination with the angiotensin receptor antagonist valsartan showed an additive antihypertensive effect in the study specifically designed to investigate the effect of the combination therapy.
Estonian: Kombinatsiooni mõju määravas spetsiaalse ülesehitusega uuringus kutsus Enviage koos valsartaaniga (angiotensiini retseptori antagonist) esile aditiivse antihüpertensiivse toime.
English: However, in one study where Enviage was used in combination with an ACEI in a diabetic population, increases in serum potassium were more frequent (5.5%).
Estonian: Seerumi kaaliumisisalduse suurenemist esines aga sagedamini (5,5%) uuringus, kus Enviage't kasutati kombinatsioonis AKE inhibiitoriga suhkurtõve patsientidel.
English: What Enviage looks like and contents of the pack Enviage 300 mg film coated tablets are light-red, biconvex, ovaloid tablets, imprinted “IU” on one side and “NVR” on the other side.
Estonian: Enviage 300 mg õhukese polümeerikattega tabletid on helepunased, kaksikkumerad, ovaalsed tabletid, mille ühel poolel on märge „IU” ja teisel „NVR”.
English: microcrystalline cellulose, povidone, colloidal anhydrous silica, talc, titanium dioxide (E 171),
Estonian: Mida Enviage sisaldab - Toimeaine on aliskireen (hemifumaraadina) 300 mg - Abiained on krospovidoon, hüpromelloos, magneesiumstearaat, makrogool, mikrokristalne tselluloos, povidoon, kolloidne veevaba ränidioksiid, talk, titaandioksiid (E 171), must raudoksiid (E 172), punane raudoksiid (E 172).
English: What Enviage looks like and contents of the pack Enviage 150 mg film coated tablets are light-pink, biconvex round tablets, imprinted “IL” on one side and “NVR” on the other side.
Estonian: Enviage 150 mg õhukese polümeerikattega tabletid on heleroosad, kaksikkumerad ümmargused tabletid, mille ühel poolel on märge „IL” ja teisel „NVR”.
English: Enviage induced an additive blood-pressure-lowering effect when added to hydrochlorothiazide and to ramipril.
Estonian: Hüdroklorotiasiidile ja ramipriilile lisamisel kutsus Enviage esile aditiivse vererõhku langetava toime.
English: NAME OF THE MEDICINAL PRODUCT Enviage 150 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Enviage 150 mg õhukese polümeerikattega tabletid
English: NAME OF THE MEDICINAL PRODUCT Enviage 150 mg film-coated tablets Aliskiren
Estonian: RAVIMPREPARAADI NIMETUS Enviage 150 mg õhukese polümeerikattega tabletid Aliskireen
English: NAME OF THE MEDICINAL PRODUCT Enviage 300 mg film-coated tablets Aliskiren
Estonian: RAVIMPREPARAADI NIMETUS Enviage 300 mg õhukese polümeerikattega tabletid Aliskireen
English: Light-pink, biconvex, round tablet, imprinted “IL” on one side and “NVR” on the other side.
Estonian: Õhukese polümeerikattega tablett Heleroosa, kaksikkumer, ümmargune tablett, mille ühel poolel on märge „IL” ja teisel „NVR”.
English: NAME OF THE MEDICINAL PRODUCT Enviage 300 mg film-coated tablets
Estonian: RAVIMPREPARAADI NIMETUS Enviage 300 mg õhukese polümeerikattega tabletid
English: Light-red, biconvex, ovaloid tablet, imprinted “IU” on one side and “NVR” on the other side.
Estonian: Õhukese polümeerikattega tablett Helepunane, kaksikkumer, ovaalne tablett, mille ühel poolel on märge „IU” ja teisel „NVR”.
English: Gastrointestinal disorders
Estonian: Neeruarteri stenoos
English: What Enviage contains - The active substance is aliskiren (as hemifumarate) 150 mg. - The other ingredients are crospovidone, hypromellose, magnesium stearate, macrogol,
Estonian: Mida Enviage sisaldab - Toimeaine on aliskireen (hemifumaraadina) 150 mg - Abiained on krospovidoon, hüpromelloos, magneesiumstearaat, makrogool, mikrokristalne tselluloos, povidoon, kolloidne veevaba ränidioksiid, talk, titaandioksiid (E 171), must raudoksiid (E 172), punane raudoksiid (E 172).
English: --1 Inactivated Coxiella burnetii, strain Nine Mile: ≥72 QF Units*/ml.
Estonian: --1 Inaktiveeritud Coxiella burnetii, tüvi Nine Mile: >72 QF ühikut*/ml *QF (Q-palaviku) ühik: suhteline tõhusus I faasi antikehade suhtes, määratakse ELISA testiga, kasutatakse võrdlusainet.
English: The average duration of response to treatment was 17.5 months.
Estonian: Ravivastuse keskmine kestus oli 17,5 kuud.
English: Further information on Imbruvica can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/imbruvica .
Estonian: Lisateave Imbruvica kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/imbruvica.
English: The side effects of the medicine were considered acceptable.
Estonian: Ravimi kõrvalnähte peeti vastuvõetavaks.
English: Imbruvica received a marketing authorisation valid throughout the EU on 21 October 2014.
Estonian: Imbruvica on saanud müügiloa, mis kehtib kogu ELis, 21. oktoobril 2014.
English: What measures are being taken to ensure the safe and effective use of Imbruvica?
Estonian: Mis meetmed võetakse, et tagada Imbruvica ohutu ja efektiivne kasutamine?
English: Imbruvica is available as capsules (140 mg) and tablets (140, 280, 420 and 560 mg).
Estonian: Imbruvicat turustatakse kapslite (140 mg) ja tablettidena (140, 280, 420 ja 560 mg).
English: The European Medicines Agency decided that Imbruvica's benefits are greater than its risks and it can be authorised for use in the EU.
Estonian: Euroopa Ravimiamet otsustas, et Imbruvica kasulikkus on suurem kui sellega kaasnevad riskid ja ravimi kasutamise võib ELis heaks kiita.
English: Imbruvica (ibrutinib)
Estonian: Imbruvica (ibrutiniib)
English: What is Imbruvica and what is it used for?
Estonian: Mis on Imbruvica ja milleks seda kasutatakse?
English: As for all medicines, data on the use of Imbruvica are continuously monitored.
Estonian: Nagu kõigi ravimite puhul, tehakse Imbruvica kasutamise kohta pidevat järelevalvet.
English: Other information about Imbruvica
Estonian: Muu teave Imbruvica kohta
English: If the patient is taking other medicines that may interact with Imbruvica, or gets severe side effects, the dose may be lowered or treatment interrupted.
Estonian: Kui patsient võtab muid ravimeid, mille korral võib esineda koostoimet Imbruvicaga, või kui tekivad rasked kõrvalnähud, võib annust vähendada või ravi katkestada.
English: Side effects reported with Imbruvica are carefully evaluated and any necessary action taken to protect patients.
Estonian: Imbruvica kõrvalnähte hinnatakse hoolikalt ja patsientide kaitseks võetakse vajalikke meetmeid.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Imbruvica have also been included in the summary of product characteristics and the package leaflet.
Estonian: Imbruvica ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on samuti lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: Why is Imbruvica authorised in the EU?
Estonian: Miks Imbruvica ELis heaks kiideti?
English: The most serious side effects are neutropenia, pneumonia (lung infection) and thrombocytopenia.
Estonian: Raskeimad kõrvalnähud on neutropeenia, pneumoonia (kopsupõletik) ja trombotsütopeenia.
English: For more information about using Imbruvica, see the package leaflet or contact your doctor or pharmacist.
Estonian: Lisateavet Imbruvica kasutamise kohta saate pakendi infolehelt või küsige oma arstilt või apteekrilt.
English: Treatment with Imbruvica should continue for as long as the disease improves or remains stable and the side effects are tolerable.
Estonian: Ravi Imbruvicaga võib jätkata, kuni patsiendi seisund paraneb või püsib stabiilsena ja kõrvalnähud on talutavad.
English: In addition Imbruvica was shown to be effective in patients with Waldenström's macroglobulinaemia..
Estonian: Peale selle oli Imbruvica tõendatult efektiivne Waldenströmi makroglobulineemiaga patsientidel.
English: Imbruvica is a medicine for treating adult patients with the following blood cancers:
Estonian: Imbruvica on ravim, mida kasutatakse järgmiste verevähi vormidega täiskasvanud patsientide raviks:
English: These diseases are rare, and Imbruvica was designated an ‘orphan medicine' (a medicine used in rare diseases) for chronic lymphocytic leukaemia on 26 April 2012, mantle cell lymphoma on 12 March 2013 and Waldenström's macroglobulinaemia on 29 April 2014.
Estonian: Need haigused esinevad harva ja Imbruvica nimetati kroonilise lümfotsüütleukeemia harvikravimiks 26. aprillil 2012, mantelrakulise lümfoomi harvikravimiks 12. märtsil 2013 ja Waldenströmi makroglobulineemia harvikravimiks 29. aprillil 2014.
English: The most common side effects with Imbruvica (which may affect more than 1 in 5 people) are diarrhoea, neutropenia (low levels of neutrophils, a type of white blood cell), pain in muscles and bones, haemorrhage (bleeding), bruising, rash, feeling sick and thrombocytopenia (low blood platelet counts).
Estonian: Imbruvica kõige sagedamad kõrvalnähud (võivad esineda enam kui 1 patsiendil 5st) on kõhulahtisus, neutropeenia (neutrofiilide ehk teatud leukotsüütide väike sisaldus), luu- ja lihasevalu, verejooks, verevalumid, lööve, iiveldus ja trombotsütopeenia (trombotsüütide ehk vereliistakute vähesus).
English: The average time before patients died or the disease got worse was 15 months with Imbruvica versus 6 months with temsirolimus.
Estonian: Keskmine aeg patsiendi surmani või haiguse progresseerumiseni oli Imbruvicaga 15 kuud ja temsiroliimusega 6 kuud.
English: • mantle cell lymphoma in patients whose disease does not respond to or has come back after previous treatment;
Estonian: • mantelrakuline lümfoom patsientidel, kelle haigus ei ole allunud varasemale ravile või on uuesti tekkinud pärast varasemat ravi;
English: What are the risks associated with Imbruvica?
Estonian: Mis riskid Imbruvicaga kaasnevad?
English: A second study in 280 such patients compared Imbruvica with another cancer medicine, temsirolimus.
Estonian: Teises uuringus, milles osales 280 sellist patsienti, võrreldi Imbruvicat temsiroliimusega (samuti vähiravim).
English: For patients with mantle cell lymphoma the dose is 560 mg once a day, for patients with chronic lymphocytic leukaemia or Waldenström's macroglobulinaemia the usual dose of Imbruvica is 420 mg once a day.
Estonian: Mantelrakulise lümfoomiga patsientide annus on 560 mg üks kord ööpäevas, kroonilise lümfotsüütleukeemiaga või Waldenströmi makroglobulineemiaga patsientide tavaannus on 420 mg üks kord ööpäevas.
English: In one main study involving 63 patients who had previously received another treatment for Waldenström's macroglobulinaemia, the disease responded to treatment with Imbruvica in 87% of patients.
Estonian: Ühes põhiuuringus, milles osales 63 patsienti, kes olid varem saanud muud Waldenströmi makroglobulineemia ravi, saavutas Imbruvicaga ravivastuse 87% patsientidest.
English: By blocking Btk, ibrutinib decreases survival and migration of B lymphocytes, thereby delaying progression of the cancer.
Estonian: Btk blokeerimisega vähendab ibrutiniib B-lümfotsüütide elumust ja levikut, lükates sellega edasi vähi progresseerumist.
English: Waldenström's macroglobulinaemia
Estonian: Waldenströmi makroglobulineemia
English: How does Imbruvica work?
Estonian: Kuidas Imbruvica toimib?
English: Imbruvica can only be obtained with a prescription, and treatment should be started and supervised by a doctor experienced in using cancer medicines.
Estonian: Ravi peab alustama ning jälgima vähiravimite kasutamises kogenud arst.
English: How is Imbruvica used?
Estonian: Kuidas Imbruvicat kasutatakse?
English: The active substance in Imbruvica, ibrutinib, works against cancerous B lymphocytes, a type of white blood cells.
Estonian: Imbruvica toimeaine ibrutiniib toimib kasvajaliste B-lümfotsüütide vastu, mis on teatud tüüpi leukotsüüdid.
English: It does this by blocking an enzyme called Bruton's tyrosine kinase (Btk), which promotes survival of B lymphocytes and their migration to the organs where these cells normally divide.
Estonian: Ibrutiniib blokeerib Brutoni türosiinkinaasi (teatud ensüüm, Btk), mis toetab Blümfotsüütide elumust ja levikut elunditesse, kus need rakud tavaliselt jagunevad.
English: In a study in 578 patients whose disease had not responded to or had come back after previous treatment, death or signs that the cancer was progressing occurred in 19% of patients (56 of 289) who took Imbruvica together with the cancer medicines bendamustine and rituximab compared with 63% (183 of 289) in those who took bendamustine and rituximab without Imbruvica.
Estonian: Uuringus, milles osales 578 patsienti, kellel haigus ei allunud varasemale ravile või tekkis pärast varasemat ravi uuesti, oli surnud või vähi progresseerumise tunnustega patsiente Imbruvicat koos vähiravimite bendamustiini ja rituksimabiga kasutanute rühmas 19% (56 patsienti 289st) ning bendamustiini ja rituksimabi ilma Imbruvicata kasutanute rühmas 63% (183 patsienti 289st).